search

1-20 of 186

Save search

Sort by

Sort Order Select

2 3 4 5

Journal Article

MEDU-06. TARGETING MYC AND OTX2-DRIVEN TRANSCRIPTIONAL DEPENDENCIES OF GROUP 3 MEDULLOBLASTOMA THROUGH CDK7 INHIBITION

PDF

Lei Zhang and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii104, https://doi.org/10.1093/neuonc/noz036.166

Published: 23 April 2019

Journal Article

MEDU-07. THE DEVELOPMENTAL STAGE OF THE MEDULLOBLASTOMA CELL-OF-ORIGIN IS MAINTAINED IN CANCER AND RESTRICTS HEDGEHOG PATHWAY USAGE AND DRUG SENSITIVITY

PDF

Marlinde Smit and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii104, https://doi.org/10.1093/neuonc/noz036.167

Published: 23 April 2019

Journal Article

MEDU-30. IDENTIFYING DISTINCTIVE lincRNAs IN THE DIFFERENT MEDULLOBLASTOMA SUBGROUPS

PDF

Shany Freedman and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii109, https://doi.org/10.1093/neuonc/noz036.188

Published: 23 April 2019

Journal Article

MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE

PDF

David Bakhshinyan and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii105, https://doi.org/10.1093/neuonc/noz036.169

Published: 23 April 2019

Journal Article

MEDU-31. IDENTIFICATION AND CHARACTERIZATION OF A NOVEL PATIENT-SPECIFIC GENE COMBINATION TO MODEL GROUP3 MEDULLOBLASTOMA

PDF

Claudio Ballabio and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii109, https://doi.org/10.1093/neuonc/noz036.189

Published: 23 April 2019

Journal Article

MEDU-24. INTERROGATING THE ROLE OF EPIGENETIC REGULATORS IN MYC-DRIVEN MEDULLOBLASTOMA

PDF

Jennifer Stripay and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii108, https://doi.org/10.1093/neuonc/noz036.183

Published: 23 April 2019

Journal Article

MEDU-11. MOLECULAR CHARACTERIZATION OF ETMRs REVEALS A ROLE FOR R-LOOP MEDIATED CHROMOSOMAL INSTABILITY

PDF

Sander Lambo and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii105, https://doi.org/10.1093/neuonc/noz036.170

Published: 23 April 2019

Journal Article

MEDU-32. IN-VIVO REPROGRAMMING OF POSTMITOTIC NEURONS INDUCES MEDULLOBLASTOMA

PDF

Giuseppe Aiello and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Pages ii109–ii110, https://doi.org/10.1093/neuonc/noz036.190

Published: 23 April 2019

Journal Article

MEDU-13. FUNCTIONAL CRISPR-CAS9 SCREEN IDENTIFIES DRUGGABLE DEPENDENCIES IN MYC-DRIVEN MEDULLOBLASTOMA

PDF

Bethany Veo and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Pages ii105–ii106, https://doi.org/10.1093/neuonc/noz036.172

Published: 23 April 2019

Journal Article

MEDU-16. MYC BUT NOT MYCN GENERATES AGGRESSIVE GROUP 3 MEDULLOBLASTOMA THROUGH ARF SUPPRESSION

PDF

Oliver Mainwaring and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii106, https://doi.org/10.1093/neuonc/noz036.175

Published: 23 April 2019

Journal Article

MEDU-38. A CASE SERIES OF CHILDREN WITH EMBRYONAL TUMOR WITH MULTILAYER ROSETTES TREATED WITH A MODIFIED IRS-III CHEMOTHERAPY BACKBONE

PDF

Derek Hanson and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii111, https://doi.org/10.1093/neuonc/noz036.196

Published: 23 April 2019

Journal Article

MEDU-20. HDAC AND NFκB ANTAGONISTS SYNERGISTICALLY INHIBIT GROWTH OF MYC-DRIVEN MEDULLOBLASTOMA

PDF

Viktoria Marquardt and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii107, https://doi.org/10.1093/neuonc/noz036.179

Published: 23 April 2019

Journal Article

MEDU-39. HIGHLY RECURRENT U1 SMALL NUCLEAR RNA HOTSPOT MUTATIONS DRIVE ALTERNATIVE SPLICING IN SONIC HEDGEHOG MEDULLOBLASTOMA

PDF

Sachin Kumar and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii111, https://doi.org/10.1093/neuonc/noz036.197

Published: 23 April 2019

Journal Article

MEDU-21. LOSS OF THE TRANSCRIPTIONAL CO-REPRESSOR BCOR LEADS TO OVEREXPRESSION OF THE GROWTH FACTOR IGF2 AND SHH MEDULLOBLASTOMA TUMOR FORMATION

PDF

Lena Kutscher and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Pages ii107–ii108, https://doi.org/10.1093/neuonc/noz036.180

Published: 23 April 2019

Journal Article

MEDU-45. DEVELOPMENT OF A NEW ETOPOSIDE-BOUND MAGNETIC NANOPARTICLE DESIGNED TO TREAT MEDULLOBLASTOMA CELLS DISSEMINATED WITHIN CEREBROSPINAL FLUID PATHWAYS

PDF

Amanda Kwasnicki and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii113, https://doi.org/10.1093/neuonc/noz036.203

Published: 23 April 2019

Journal Article

MEDU-47. A NOVEL TGF-BETA/MYC-DRIVEN MEDULLOBLASTOMA MODEL TO STUDY IMMUNE-TUMOR INTERACTIONS

PDF

Jacob Henderson and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii113, https://doi.org/10.1093/neuonc/noz036.205

Published: 23 April 2019

Journal Article

MEDU-33. HUMAN CEREBELLAR ORGANOIDS AS A NEW 3D MODEL OF MEDULLOBLASTOMA

PDF

Marica Anderle and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii110, https://doi.org/10.1093/neuonc/noz036.191

Published: 23 April 2019

Journal Article

MEDU-34. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA

PDF

Kenneth Cohen and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii110, https://doi.org/10.1093/neuonc/noz036.192

Published: 23 April 2019

Journal Article

MEDU-14. GENOMIC ANALYSIS OF ETMR GUIDES EFFICACIOUS DFMO DRUG COMBINATIONS

PDF

Austin Goodyke and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii106, https://doi.org/10.1093/neuonc/noz036.173

Published: 23 April 2019

Journal Article

MEDU-15. STRUCTURAL BRAIN NETWORK PROPERTIES AND COGNITIVE IMPAIRMENT IN ADOLESCENTS AFTER RADIATION THERAPY

PDF

Justin Yuan and others

Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii106, https://doi.org/10.1093/neuonc/noz036.174

Published: 23 April 2019

2 3 4 5

Modify your search

Availability

NARROW

Format

Type

Section

Publication date

MEDU-06. TARGETING MYC AND OTX2-DRIVEN TRANSCRIPTIONAL DEPENDENCIES OF GROUP 3 MEDULLOBLASTOMA THROUGH CDK7 INHIBITION

MEDU-07. THE DEVELOPMENTAL STAGE OF THE MEDULLOBLASTOMA CELL-OF-ORIGIN IS MAINTAINED IN CANCER AND RESTRICTS HEDGEHOG PATHWAY USAGE AND DRUG SENSITIVITY

MEDU-30. IDENTIFYING DISTINCTIVE lincRNAs IN THE DIFFERENT MEDULLOBLASTOMA SUBGROUPS

MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE

MEDU-31. IDENTIFICATION AND CHARACTERIZATION OF A NOVEL PATIENT-SPECIFIC GENE COMBINATION TO MODEL GROUP3 MEDULLOBLASTOMA

MEDU-24. INTERROGATING THE ROLE OF EPIGENETIC REGULATORS IN MYC-DRIVEN MEDULLOBLASTOMA

MEDU-11. MOLECULAR CHARACTERIZATION OF ETMRs REVEALS A ROLE FOR R-LOOP MEDIATED CHROMOSOMAL INSTABILITY

MEDU-32. IN-VIVO REPROGRAMMING OF POSTMITOTIC NEURONS INDUCES MEDULLOBLASTOMA

MEDU-13. FUNCTIONAL CRISPR-CAS9 SCREEN IDENTIFIES DRUGGABLE DEPENDENCIES IN MYC-DRIVEN MEDULLOBLASTOMA

MEDU-16. MYC BUT NOT MYCN GENERATES AGGRESSIVE GROUP 3 MEDULLOBLASTOMA THROUGH ARF SUPPRESSION

MEDU-38. A CASE SERIES OF CHILDREN WITH EMBRYONAL TUMOR WITH MULTILAYER ROSETTES TREATED WITH A MODIFIED IRS-III CHEMOTHERAPY BACKBONE

MEDU-20. HDAC AND NFκB ANTAGONISTS SYNERGISTICALLY INHIBIT GROWTH OF MYC-DRIVEN MEDULLOBLASTOMA

MEDU-39. HIGHLY RECURRENT U1 SMALL NUCLEAR RNA HOTSPOT MUTATIONS DRIVE ALTERNATIVE SPLICING IN SONIC HEDGEHOG MEDULLOBLASTOMA

MEDU-21. LOSS OF THE TRANSCRIPTIONAL CO-REPRESSOR BCOR LEADS TO OVEREXPRESSION OF THE GROWTH FACTOR IGF2 AND SHH MEDULLOBLASTOMA TUMOR FORMATION

MEDU-45. DEVELOPMENT OF A NEW ETOPOSIDE-BOUND MAGNETIC NANOPARTICLE DESIGNED TO TREAT MEDULLOBLASTOMA CELLS DISSEMINATED WITHIN CEREBROSPINAL FLUID PATHWAYS

MEDU-47. A NOVEL TGF-BETA/MYC-DRIVEN MEDULLOBLASTOMA MODEL TO STUDY IMMUNE-TUMOR INTERACTIONS

MEDU-33. HUMAN CEREBELLAR ORGANOIDS AS A NEW 3D MODEL OF MEDULLOBLASTOMA

MEDU-34. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA

MEDU-14. GENOMIC ANALYSIS OF ETMR GUIDES EFFICACIOUS DFMO DRUG COMBINATIONS

MEDU-15. STRUCTURAL BRAIN NETWORK PROPERTIES AND COGNITIVE IMPAIRMENT IN ADOLESCENTS AFTER RADIATION THERAPY

Email alerts

Modify your search

Publication date

MEDU-06. TARGETING MYC AND OTX2-DRIVEN TRANSCRIPTIONAL DEPENDENCIES OF GROUP 3 MEDULLOBLASTOMA THROUGH CDK7 INHIBITION Free

MEDU-07. THE DEVELOPMENTAL STAGE OF THE MEDULLOBLASTOMA CELL-OF-ORIGIN IS MAINTAINED IN CANCER AND RESTRICTS HEDGEHOG PATHWAY USAGE AND DRUG SENSITIVITY Free

MEDU-30. IDENTIFYING DISTINCTIVE lincRNAs IN THE DIFFERENT MEDULLOBLASTOMA SUBGROUPS Free

MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE Free

MEDU-31. IDENTIFICATION AND CHARACTERIZATION OF A NOVEL PATIENT-SPECIFIC GENE COMBINATION TO MODEL GROUP3 MEDULLOBLASTOMA Free

MEDU-24. INTERROGATING THE ROLE OF EPIGENETIC REGULATORS IN MYC-DRIVEN MEDULLOBLASTOMA Free

MEDU-11. MOLECULAR CHARACTERIZATION OF ETMRs REVEALS A ROLE FOR R-LOOP MEDIATED CHROMOSOMAL INSTABILITY Free

MEDU-32. IN-VIVO REPROGRAMMING OF POSTMITOTIC NEURONS INDUCES MEDULLOBLASTOMA Free

MEDU-13. FUNCTIONAL CRISPR-CAS9 SCREEN IDENTIFIES DRUGGABLE DEPENDENCIES IN MYC-DRIVEN MEDULLOBLASTOMA Free

MEDU-16. MYC BUT NOT MYCN GENERATES AGGRESSIVE GROUP 3 MEDULLOBLASTOMA THROUGH ARF SUPPRESSION Free

MEDU-38. A CASE SERIES OF CHILDREN WITH EMBRYONAL TUMOR WITH MULTILAYER ROSETTES TREATED WITH A MODIFIED IRS-III CHEMOTHERAPY BACKBONE Free

MEDU-20. HDAC AND NFκB ANTAGONISTS SYNERGISTICALLY INHIBIT GROWTH OF MYC-DRIVEN MEDULLOBLASTOMA Free

MEDU-39. HIGHLY RECURRENT U1 SMALL NUCLEAR RNA HOTSPOT MUTATIONS DRIVE ALTERNATIVE SPLICING IN SONIC HEDGEHOG MEDULLOBLASTOMA Free

MEDU-21. LOSS OF THE TRANSCRIPTIONAL CO-REPRESSOR BCOR LEADS TO OVEREXPRESSION OF THE GROWTH FACTOR IGF2 AND SHH MEDULLOBLASTOMA TUMOR FORMATION Free

MEDU-45. DEVELOPMENT OF A NEW ETOPOSIDE-BOUND MAGNETIC NANOPARTICLE DESIGNED TO TREAT MEDULLOBLASTOMA CELLS DISSEMINATED WITHIN CEREBROSPINAL FLUID PATHWAYS Free

MEDU-47. A NOVEL TGF-BETA/MYC-DRIVEN MEDULLOBLASTOMA MODEL TO STUDY IMMUNE-TUMOR INTERACTIONS Free

MEDU-33. HUMAN CEREBELLAR ORGANOIDS AS A NEW 3D MODEL OF MEDULLOBLASTOMA Free

MEDU-34. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA Free

MEDU-14. GENOMIC ANALYSIS OF ETMR GUIDES EFFICACIOUS DFMO DRUG COMBINATIONS Free

MEDU-15. STRUCTURAL BRAIN NETWORK PROPERTIES AND COGNITIVE IMPAIRMENT IN ADOLESCENTS AFTER RADIATION THERAPY Free

Email alerts

This Feature Is Available To Subscribers Only

MEDU-06. TARGETING MYC AND OTX2-DRIVEN TRANSCRIPTIONAL DEPENDENCIES OF GROUP 3 MEDULLOBLASTOMA THROUGH CDK7 INHIBITION

MEDU-07. THE DEVELOPMENTAL STAGE OF THE MEDULLOBLASTOMA CELL-OF-ORIGIN IS MAINTAINED IN CANCER AND RESTRICTS HEDGEHOG PATHWAY USAGE AND DRUG SENSITIVITY

MEDU-30. IDENTIFYING DISTINCTIVE lincRNAs IN THE DIFFERENT MEDULLOBLASTOMA SUBGROUPS

MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE

MEDU-31. IDENTIFICATION AND CHARACTERIZATION OF A NOVEL PATIENT-SPECIFIC GENE COMBINATION TO MODEL GROUP3 MEDULLOBLASTOMA

MEDU-24. INTERROGATING THE ROLE OF EPIGENETIC REGULATORS IN MYC-DRIVEN MEDULLOBLASTOMA

MEDU-11. MOLECULAR CHARACTERIZATION OF ETMRs REVEALS A ROLE FOR R-LOOP MEDIATED CHROMOSOMAL INSTABILITY

MEDU-32. IN-VIVO REPROGRAMMING OF POSTMITOTIC NEURONS INDUCES MEDULLOBLASTOMA

MEDU-13. FUNCTIONAL CRISPR-CAS9 SCREEN IDENTIFIES DRUGGABLE DEPENDENCIES IN MYC-DRIVEN MEDULLOBLASTOMA

MEDU-16. MYC BUT NOT MYCN GENERATES AGGRESSIVE GROUP 3 MEDULLOBLASTOMA THROUGH ARF SUPPRESSION

MEDU-38. A CASE SERIES OF CHILDREN WITH EMBRYONAL TUMOR WITH MULTILAYER ROSETTES TREATED WITH A MODIFIED IRS-III CHEMOTHERAPY BACKBONE

MEDU-20. HDAC AND NFκB ANTAGONISTS SYNERGISTICALLY INHIBIT GROWTH OF MYC-DRIVEN MEDULLOBLASTOMA

MEDU-39. HIGHLY RECURRENT U1 SMALL NUCLEAR RNA HOTSPOT MUTATIONS DRIVE ALTERNATIVE SPLICING IN SONIC HEDGEHOG MEDULLOBLASTOMA

MEDU-21. LOSS OF THE TRANSCRIPTIONAL CO-REPRESSOR BCOR LEADS TO OVEREXPRESSION OF THE GROWTH FACTOR IGF2 AND SHH MEDULLOBLASTOMA TUMOR FORMATION

MEDU-45. DEVELOPMENT OF A NEW ETOPOSIDE-BOUND MAGNETIC NANOPARTICLE DESIGNED TO TREAT MEDULLOBLASTOMA CELLS DISSEMINATED WITHIN CEREBROSPINAL FLUID PATHWAYS

MEDU-47. A NOVEL TGF-BETA/MYC-DRIVEN MEDULLOBLASTOMA MODEL TO STUDY IMMUNE-TUMOR INTERACTIONS

MEDU-33. HUMAN CEREBELLAR ORGANOIDS AS A NEW 3D MODEL OF MEDULLOBLASTOMA

MEDU-34. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA

MEDU-14. GENOMIC ANALYSIS OF ETMR GUIDES EFFICACIOUS DFMO DRUG COMBINATIONS

MEDU-15. STRUCTURAL BRAIN NETWORK PROPERTIES AND COGNITIVE IMPAIRMENT IN ADOLESCENTS AFTER RADIATION THERAPY